Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor gamma alternate reading frame protein (TARP) is a small intracellular protein (7 kDa) expressed from an alternative reading frame of the T cell receptor gamma (TCRG) gene locus. Originally identified in the prostate, TARP is also upregulated in androgen-dependent prostate cancer cells and present in certain breast cancer cell lines, while not expressed by infiltrating T lymphocytes in these tissues. TARP localizes primarily to the mitochondria, specifically the outer mitochondrial membrane in cancer cells, and is thought to play a role in mitochondrial function and possibly as a dimerization motif due to its leucine zipper sequence. TARP is being investigated as a cancer-testis antigen and a target for immunotherapeutic strategies, including TCR (T cell receptor) engineered therapies for prostate cancer, breast cancer, and acute myeloid leukemia. Its distinct intracellular expression and cancer specificity make it a promising biomarker and therapeutic target for certain malignancies.
Immune targeting—engineered T cells recognize and kill TARP-expressing cancer cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor gamma alternate reading frame protein (TARP).